24-26 October


Keynote speakers

Leading experts in their fields

About Lisbon Addictions 2017

Lisbon Addictions 2017, the second European Conference on Addictive Behaviours and Dependencies, is a multidisciplinary conference that provides a forum for networking across the addictions.

Over 600 participants from 58 countries attended Lisbon Addictions 2015. The conference sold out several months before the event. See presentations and posters

Following this success, the organisers have decided to launch Lisbon Addictions 2017, which will take place in the Lisboa Congress Centre (a new venue, which can accommodate up to 850 participants), from 24 to 26 October 2017.

Once again, the conference will be jointly organised by the Portuguese General Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), the journal Addiction, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the International Society of Addiction Journal Editors (ISAJE).

Please note that Lisbon has become a popular location for many congresses and other major events. We strongly advise you to book your hotel well in advance by using the Cityrama.

Looking for a tips on exploring Lisbon and nearby destinations? Our local partners have arranged for a tour organising company to be on site at LxAddictions17, but you may already select and book your tours and visits at Cityrama.

Subscribe to our newsletter

Key dates

27 October 2016: Registration and call for abstracts open
15 March 2017: Deadline for abstracts
31 March 2017: Deadline for early-bird registration fee (EUR 350)
3 April 2017: Submission for late-breaking abstracts opens
31 May 2017: Notification to authors (except late-breaking)
30 June 2017: Deadline for regular registration (EUR 400)
31 July 2017: Deadline for late-breaking abstracts
24–26 October 2017: Conference


The conference is organised around three overarching themes.

Understanding addictions

Under this theme we welcome presentations that provide a state of the art understanding of the nature, scale and impact of addictive behaviours, their health, behavioural, social correlates, and how addictions can be theoretically constructed.

From evidence to action

Under this theme we welcome research findings that inform the development, targeting and delivery of effective policies and interventions across the addictions field

Addiction horizons

Under this theme we welcome presentations that extend the frontiers of addiction knowledge, identify new threats and challenges and highlight new opportunities for action.

  • Constructing addictions: theories, methodology and measurement
  • Clinical tools
  • Learning from history
  • Demographic challenges
  • Social inequalities
  • Multiple voices (inc. the role of civil society and user perspectives)
  • Research: ethics, methods and practice
  • Education and training in addictions
  • Public health policies
  • Policy and programme evaluation
  • Prevention: theory and practice
  • Lessons for clinical practice
  • Reducing risks
  • Integrating care models and partnerships
  • Understanding health consequences
  • Responding to diversity  (including gender issues)
  • New developments in NPS
  • Understanding and regulating drug markets
  • Drug related crime and the illicit market
  • Specific target populations
  • Developments in basic research
  • Dynamics and change (new trends)
  • New methods and analysis
  • Impact of new technologies
  • E-health

The programme will be organised/developed around plenary sessions, oral presentations in open sessions, structured sessions (symposia/panel discussions/workshops) and poster presentations. Sessions are scheduled in different time slots commencing Tuesday 24 October and closing on Thursday 26 October. All participants should ensure their availability for all time slots.

Side events and networking

LxAddictions17 will again provide a unique networking opportunity for researchers, practitioners and policy experts across countries and disciplines, addressing new challenges and covering developing fields. In the margins of the conference various major events will take place. Already confirmed are the following:

Please note that participants need to register separately for side‑events.

To promote networking, conference rooms will be available for side events. If interested please contact us at: lisbonaddictions2017@abreu.pt

Looking for a tips on exploring Lisbon and nearby destinations? Our local partners have arranged for a tour organising company to be on site at LxAddictions17, but you may already select and book your tours and visits at Cityrama.

Call for abstracts

The deadline for submitting abstracts ended 15 March 2017.

Delegates will be informed if their contribution has been accepted for inclusion in the conference programme by 31 May 2017.

Late-breaking abstracts may be submitted from 3 April to 31 July but only a limited number will be accepted. Download detailed abstract guidelines here.


Online registration is now open. Places for non-presenters will be allocated on a first come, first served basis. All persons intending to attend the conference must register and pay the applicable registration fee, including paper and poster presenters, discussants and chairs.

The conference registration fee is EUR 400 (until 30 June) and EUR 500 for those registering after this date.

Register now



Praça das Indústrias
1300-307 Lisboa

Tel: (+351) 21 360 1400

Fax: (+351) 21 360 1499



Avenida 25 de Abril, 2
2799-556 Linda-a-Velha

Tel: (+351) 21 415 6120

Fax: (+351) 21 415 6383

E-mail: helder.carvalho@abreu.pt


Please contact the local exhibition management company to receive further information about the exhibition (set-up, dismantling, stands, furniture, terms & conditions, order forms, etc.)


  • Judith Aldridge (Senior Lecturer, School of Law, University of Manchester, UK)
  • Hannu Alho (ISAM  President, Professor of Addiction Medicine, Finland)
  • Alexander Baldacchino (Professor of Medicine, Psychiatry and Addictions, University of St Andrews, UK)
  • Henri Bergeron (Chair in Health Studies, Sciences Po Paris, France)
  • Virginia Berridge (Professor of History and Director, Centre for History in Public Health, London School of Hygiene and Tropical Medicine, UK)
  • Kim Bloomfield (Professor, Center for Alcohol and Drug Research, Aarhus University, Denmark)
  • Henrietta Bowden-Jones (Consultant Psychiatrist. Founder and Director, National Problem Gambling Clinic, UK)
  • Jørgen G. Bramness (Senior researcher, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Norwegian Centre of Dual Diagnosis)
  • Anne Line Bretteville-Jensen (Research Director, Norwegian Institute for Alcohol and Drug Research (SIRUS), Norway)
  • Angelina Brotherhood (Public Health Researcher, Liverpool John Moores University, UK)
  • Gerhard Bühringer (Chair of Addiction Research, Institute for Clinical Psychology and Psychotherapy, Technische Universität Dresden, Germany)
  • Catherine Comiskey (Head of School of Nursing and Midwifery, Trinity College, Ireland)
  • Ornella Corazza (Reader in Substance Addictions and Behaviours, University of Hertfordshire, Hatfield, UK)
  • Paul Dargan (Consultant Physician and Clinical Toxicologist, Guy's and St Thomas' NHS Foundation Trust, and Reader in Toxicology, King’s College London, UK)
  • Marina Davoli (Head, Department of Epidemiology, National Agency for Health Services, Italy)
  • Louisa Degenhardt (Professor, National Drug and Alcohol Research Centre (NDARC), Australia)
  • Fernando Rodríguez de Fonseca (Fundación IMABIS, Hosp. Univ. Carlos Haya de Málaga, Spain)
  • Brice de Ruyver (Full Professor criminal law and criminology, Director Institute for International Research on Criminal Policy, Ghent University, Belgium)
  • Fabrizio Faggiano (Professor of Public Health at the Department of Translational Medicine of the University of the Piemonte Orientale, Italy)
  • Michael Farrell (Director, National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Australia)
  • Gabriele Fischer (Medical Director of the Addiction Clinic at the Medical University Vienna, Austria)
  • Henk Garretsen (Professor, Director Tranzo, Scientific Centre for Care and Welfare, Tilburg University, The Netherlands)
  • Eilish Gilvarry (President of the Society for the Study of Addiction, Honorary Professor of Addiction Psychiatry, Newcastle University, UK)
  • Manuela Grazina (Professor, Faculty of Medicine; Researcher and Head of Laboratory of Biochemical Genetics, Center for Neuroscience and Cell Biology; University of Coimbra, Portugal)
  • Antoni Gual (Director of the Addictions Unit, Hospital Clínic Barcelona, Spain)
  • Wayne Hall (Professor, Director and Inaugural Chair, Centre for Youth Substance Abuse Research, The University of Queensland, Australia)
  • Matthew Hickman (School of Social and Community Medicine, University of Bristol, UK)
  • Susana Jiménez-Murcia (Head of Pathological Gambling Unit, Department of Psychiatry, University Hospital of Bellvitge, Barcelona, Spain)
  • Beau Kilmer (Co-director and senior policy researcher, RAND Drug Policy Research Center; Professor, Pardee RAND Graduate School, USA)
  • Dirk Korf (Professor, Bonger Institute of Criminology, University of Amsterdam, The Netherlands)
  • Krzysztof Krajewski (Chair of Criminology, Jagiellonian University, Poland)
  • Ludwig Kraus (Director, IFT Institut für Therapieforschung, Munich, Germany)
  • Håkan Leifman (Director, Swedish Council for Information on Alcohol and Other Drugs (CAN), Sweden)
  • Henrique Lopes (President of the Ibero-latin-american Scientific Society for Gambling Research, Chair of CEIA research center, researcher at Public Healthcare Unit of Catholic University - ICS)
  • Pia Mäkelä (Head of Alcohol and Drugs Unit, National Institute for Health and Welfare, Finland)
  • Meni Malliori (Associate Professor of Psychiatry, Medical School, National & Kapodistrian University of Athens, Greece)
  • Rebecca McKetin (Associate Professor, ANU College of Medicine, Biology and Environment, Australia)
  • Angela Me (Chief of the Research and and Trend Analysis Branch, United Nations Office on Drugs and Crime)
  • Catherine Moury (Assistant Professor of political Science, FCSH, Universidade Nova de Lisboa, Portugal)
  • Emília Nunes (Professor, Director of the National Programme for Prevention of Smoking and Tobacco Control, General-Directorate of Health, Portugal)
  • Letizia Paoli (Professor, Leuven Institute of Criminology, University of Leuven, Faculty of Law, Belgium)
  • Amy Porath-Waller (Director, Research and Policy, Canadian Centre on Substance Abuse, Canada)
  • Jürgen Rehm (Director, Social and Epidemiological Research (SER) Department, Centre for Addiction and Mental Health, Toronto, Canada)
  • Xavier Majó i Roca (Office of Drug Addiction, Public Health Agency of Catalonia, Spain)
  • Zila M. Sanchez (Professor of Epidemiology, Preventive Medicine Department, Universidade Federal de São Paulo, Brazil)
  • Emanuele Scafato (Director of Population’s Health and Health Determinants Unit in the National Centre for Epidemiology, Surveillance and Health Promotion-CNESPS at the Istituto Superiore di Sanità, Italy)
  • Janusz Sieroslawski (Institute of Psychiatry and Neurology, Poland)
  • Jussi Simpura (Chair, Finnish Foundation for Alcohol Studies)
  • Zili Sloboda (President, Applied Prevention Science, Inc., USA)
  • Rainer Spanagel (Professor of Pharmacology & Toxicology, Head of the Institute of Psychopharmacology, University of Heidelberg, Germany)
  • Kerstin Stenius (Ass. Prof., Centre for Social Research on Alcohol and Drugs, Stockholm University, Sweden; Alcohol and Drugs unit, National Institute for Health and Welfare, Finland; and Nordic Centre for Welfare and Social Issues, Finland)
  • John Strang (Professor, Head of the Addictions Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, UK)
  • Harry Sumnall (Professor, Centre for Public Health, Liverpool John Moores University, UK)
  • Margriet Van Laar (Head of the Department Drug Monitoring, Trimbos Institute, The Netherlands)
  • Julian Vicente (Head of the prevalence, consequences and data management unit, EMCDDA)
  • Graça Vilar (Director of the Planning and Intervention Department of SICAD, Master in forensic medicine and forensic sciences, Graduate Assistant of Psychiatry Hospital, Portugal)
  • Chris Wilkins (Senior Researcher, Drugs Team Leader, SHORE & Whariki Research Centre, College of Health, Massey University, Auckland, New Zealand)

Co-chairs: Manuel Cardoso (SICAD), Paul Griffiths (EMCDDA)

  • Robert West (Addiction/Society for the Study of Addiction)
  • Ann McNeill (Addiction/Society for the Study of Addiction)
  • Richard Pates (ISAJE)
  • Michal Miovsky (ISAJE)
  • Ana Sofia Santos (SICAD)
  • Ana Rodrigues (SICAD)
  • Maria Moreira (EMCDDA)
  • Liesbeth Vandam (EMCDDA)
  • Manuel Cardoso (SICAD)
  • Ana Sofia Santos (SICAD)
  • Ana Rodrigues (SICAD)
  • Filipa Cunha (SICAD)
  • Paula Andrade (SICAD)
  • Alexandra Pinto (SICAD)
  • Paul Griffiths (EMCDDA)
  • Maria Moreira (EMCDDA)
  • Liesbeth Vandam (EMCDDA)
  • Marie-Christine Ashby (EMCDDA)
  • Silke Vitt (EMCDDA)
  • Renate Hochwieser (EMCDDA)
  • Prem Borle (EMCDDA)